VK2735 makes Viking Therapeutics an attractive buyout candidate or big pharma partner. Its oral formulation reported good ...

Viking Therapeutics is primed for acquisition due to its robust pipeline and potential as a market disruptor. Find out why ...

Viking currently boasts a market valuation of $8.1 billion. For an unprofitable biotech company without approved products, ...

Continue reading But if VK2735 passes phase 3 studies with flying colors, that should jolt the company's stock again.

Q1 2024 Earnings Call Transcript April 24, 2024 Viking Therapeutics, Inc. beats earnings expectations. Reported EPS is $-0.26 ...

In terms of liquidity and interest, the mean open interest for Viking Therapeutics options trades today is 783.0 with a total ...

Key Insights Significantly high institutional ownership implies Viking Therapeutics' stock price is sensitive to ...

In this match-up, Pfizer arguably stands out as the more attractive investment. The company's stock is less risky, offers a ...

In terms of liquidity and interest, the mean open interest for Viking Therapeutics options trades today is 1418.18 with a ...

Viking Therapeutics (NASDAQ:VKTX) just reported results for the first quarter of 2024. Viking Therapeutics reported earnings per share of -26 cents. This was above the analyst estimate for EPS of ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...